Etoposide (VP16) in the treatment of multisystem langerhans cell histiocytosis (histiocytosis X)
- 1 January 1989
- journal article
- research article
- Published by Wiley in Medical and Pediatric Oncology
- Vol. 17 (2), 97-100
- https://doi.org/10.1002/mpo.2950170205
Abstract
Ten children with Langerhans cell histiocytosis (histiocytosis X) either resistant to or intolerant of corticosteroids received etoposide (VP16). Nine responded. In one instance, partial diabetes insipidus was temporarily reversed. There was no major toxicity. Etoposide should be seriously considered as therapy for patients with LCH in whom the toxicity/benefit ratio of steroid therapy is unacceptably high.Keywords
This publication has 9 references indexed in Scilit:
- A short water deprivation test incorporating urinary arginine vasopressin estimations for the investigation of posterior pituitary function in childrenActa Endocrinologica, 1988
- Multifocal eosinophilic granuloma: Response of a patient to etoposideCancer, 1986
- Histiocytosis X presenting as intertrigo and responding to topical nitrogen mustardClinical and Experimental Dermatology, 1986
- Histiocytosis X--current controversies.Archives of Disease in Childhood, 1985
- SPONTANEOUS REMISSION OF MULTI-SYSTEM HISTIOCYTOSIS XThe Lancet, 1984
- Successful treatment of lymphohistiocytic reticulosis with phagocytosis with epipodophyllotoxin VP 16–213Cancer, 1980
- Histiocytosis X: natural history and management in childhoodClinical and Experimental Dermatology, 1979
- Histiocytosis X—an analysis of prognostic factorsThe Journal of Pediatrics, 1975
- Histiocytosis X—comparison of three treatment regimensThe Journal of Pediatrics, 1975